HighTower Advisors’s Purple Biotech PPBT Stock Holding History

HighTower Advisors’s Portfolio PPBT Stock Details PPBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-6	Closed	-$12K	–	2659
2020 Q2	$12K	Buy	+6	New	+$5.9K	﹤0.01%	2298

Other funds holding PPBT

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

ECM

ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFC

Bedel Financial Consulting Indianapolis, Indiana $888M AUM 19.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TPWA

TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HighTower Advisors's PPBT Position: Q3 2020 in Review

HighTower Advisors sold out of Purple Biotech (PPBT) in Q3 2020, closing a stake of 6 shares — an estimated $12K sold.

HighTower Advisors first reported a position in PPBT in Q2 2020 and held it in 1 quarter. The position peaked at $12K in Q2 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q3 2020.

HighTower Advisors reported no remaining Purple Biotech position as of Q3 2020 after selling out during the quarter.
HighTower Advisors sold 6 Purple Biotech shares in Q3 2020, an estimated $12K.
HighTower Advisors first reported a position in Purple Biotech in Q2 2020 and held it in 1 quarter.
HighTower Advisors's Purple Biotech position peaked at $12K in Q2 2020.
15 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2020.

Based on HighTower Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.